Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection (Q33877260)

29 July 2017

1 reference

title

Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection (English)

1 reference

29 July 2017

Stone TW

1

0 references

publication date

1 April 2000

1 reference

Trends in Pharmacological Sciences

29 July 2017

1 reference

29 July 2017

21

1 reference

29 July 2017

149-154

1 reference

29 July 2017

4

1 reference

Glutamate-induced mitochondrial depolarisation and perturbation of calcium homeostasis in cultured rat hippocampal neurones

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

Actions of excitatory amino acids and kynurenic acid in the primate hippocampus: a preliminary study.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

Sensitivity of hippocampal neurones to kainic acid, and antagonism by kynurenate

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

4-Amido-2-carboxytetrahydroquinolines. Structure-activity relationships for antagonism at the glycine site of the NMDA receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

3'-(Arylmethyl)- and 3'-(aryloxy)-3-phenyl-4-hydroxyquinolin-2(1H)-ones: orally active antagonists of the glycine site on the NMDA receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

3-Nitro-3,4-dihydro-2(1H)-quinolones. Excitatory amino acid antagonists acting at glycine-site NMDA and (RS)-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

Indole-2-carboxylates, novel antagonists of the N-methyl-D-aspartate (NMDA)-associated glycine recognition sites: in vivo characterization.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

Neuroprotective effects of RPR 104632, a novel antagonist at the glycine site of the NMDA receptor, in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

Binding of the radiolabeled glycine site antagonist [3H]MDL 105,519 to homomeric NMDA-NR1a receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

Facilitated brain uptake of 4-chlorokynurenine and conversion to 7-chlorokynurenic acid.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

Human microglia convert l-tryptophan into the neurotoxin quinolinic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

Activated human microglia produce the excitotoxin quinolinic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

Sources of the neurotoxin quinolinic acid in the brain of HIV-1-infected patients and retrovirus-infected macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

Neurobiological aspects of human immunodeficiency virus infection: neurotoxic mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

Nicotinylalanine increases cerebral kynurenic acid content and has anticonvulsant activity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

Quinolinic acid lesion of the nigrostriatal pathway: effect on turning behaviour and protection by elevation of endogenous kynurenic acid in Rattus norvegicus.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

Modulation of the kynurenine pathway in search for new neuroprotective agents. Synthesis and preliminary evaluation of (m-nitrobenzoyl)alanine, a potent inhibitor of kynurenine-3-hydroxylase.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

Comparison of the neurochemical and behavioral effects resulting from the inhibition of kynurenine hydroxylase and/or kynureninase

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

(R,S)-3,4-dichlorobenzoylalanine (FCE 28833A) causes a large and persistent increase in brain kynurenic acid levels in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

Kynurenine hydroxylase inhibitors reduce ischemic brain damage: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(nitrophenyl)thiazol-2yl]-benzenesulfonamide (Ro 61-8048) in models of focal or global brain ischemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

Quinolinic acid formation in immune-activated mice: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(-3-nitrophenyl)thiazol-2yl]-benzenesul fonamide (Ro 61-8048), two potent and selective inhibitors of kynurenine hydroxylase.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

Pyrrolo[3,2-c]quinoline derivatives: a new class of kynurenine-3-hydroxylase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

4-Phenyl-4-oxo-butanoic acid derivatives inhibitors of kynurenine 3-hydroxylase.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

Quantitative differences in the effects of de novo produced and exogenous kynurenic acid in rat brain slices

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

Effects of 540C91 [(E)-3-[2-(4'-pyridyl)-vinyl]-1H-indole], an inhibitor of hepatic tryptophan dioxygenase, on brain quinolinic acid in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

Metabolism of L-tryptophan to kynurenate and quinolinate in the central nervous system: effects of 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

Effects of the 3-hydroxyanthranilic acid analogue NCR-631 on anoxia-, IL-1 beta- and LPS-induced hippocampal pyramidal cell loss in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

The glycine antagonist GV150526 protects somatosensory evoked potentials and reduces the infarct area in the MCAo model of focal ischemia in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

Safety and tolerability of GV150526 (a glycine site antagonist at the N-methyl-D-aspartate receptor) in patients with acute stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

Cycloalkyl indole-2-carboxylates as useful tools for mapping the "north-eastern" region of the glycine binding site associated with the NMDA receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

A glycine site antagonist, ZD9379, reduces number of spreading depressions and infarct size in rats with permanent middle cerebral artery occlusion.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

Protective and symptomatic strategies for therapy of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

Kynurenine pathway abnormalities in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

Schizophrenia and glutamatergic transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901451-6

7 January 2021

10.1016/S0165-6147(00)01451-6

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10740291